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Abstract
Ocular exposure to influenza virus represents an alternate route of virus entry capable of 
establishing a respiratory infection in mammals, but the effectiveness of currently available 
antiviral treatments to limit virus replication within ocular tissue or inhibit virus spread from 
ocular sites to the respiratory tract is poorly understood. Using an inoculation method that delivers 
an aerosol inoculum exclusively to the ocular surface, we demonstrate that oral oseltamivir 
administration following ocular-only aerosol inoculation with multiple avian and human influenza 
viruses protected ferrets from a fatal and systemic infection, reduced clinical signs and symptoms 
of illness, and decreased virus transmissibility to susceptible contacts when a respiratory infection 
was initiated. The presence of oseltamivir further inhibited influenza virus replication in primary 
human corneal epithelial cells. These findings provide critical experimental evidence supporting 
the use of neuraminidase inhibitors during outbreaks of influenza virus resulting in ocular disease 
or following ocular exposure.
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Introduction
Influenza virus is a highly contagious respiratory pathogen; high viral loads are expelled 
during coughing and sneezing of infected individuals, and inhalation of virus-containing 
aerosols by susceptible contacts represents a principal route of human infection (Milton et 
al., 2013; Tellier, 2009). However, like many respiratory pathogens, ocular exposure to 
influenza viruses constitutes a secondary route of virus entry, with the eye representing both 
a potential site of virus replication as well as a portal for establishing a respiratory infection 
(Belser et al., 2013b). While H7 subtype influenza viruses have typically been associated 
with ocular exposure and disease in humans, reports of both avian and human influenza 
viruses causing conjunctivitis have been documented (Belser et al., 2013b). Furthermore, 
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ocular inoculation of mammalian models has demonstrated the ability of select influenza 
viruses to cause a fatal infection following ocular exposure, or to maintain a transmissible 
phenotype following ocular exposure, even in the absence of an ocular tropism (Belser et al., 
2014, 2012a). Still, ocular exposure remains a poorly understood route of viral entry, 
limiting our ability to study effective treatment options in humans exposed to influenza 
viruses by the ocular route or presenting with ocular symptoms.
Neuraminidase (NA) inhibitors represent the most widely used class of antiviral drug to treat 
individuals presenting with respiratory symptoms of influenza virus infection (Ison, 2015). 
Early administration of the NA inhibitor oseltamivir is associated with reduced clinical signs 
and symptoms of infection and reduced viral loads in respiratory tract tissues; oseltamivir 
prophylaxis is frequently prescribed during outbreaks of avian influenza virus where there is 
a risk of occupational exposure to the virus (Koopmans et al., 2004; Writing Committee of 
the Second World Health Organization Consultation on Clinical Aspects of Human Infection 
et al., 2008). Despite a paucity of experimental evidence examining the efficacy of antiviral 
treatments following infection by non-respiratory exposure routes, oseltamivir treatment and 
prophylaxis has nonetheless been prescribed during outbreaks in humans where 
conjunctivitis and/or ocular exposure has been reported (Koopmans et al., 2004; Tweed et 
al., 2004). Oral oseltamivir treatment has been shown to reduce viral pathogenesis and limit 
virus transmissibility in numerous mammalian models following inoculation with influenza 
viruses, though these studies have been limited to respiratory inoculation routes (Govorkova 
et al., 2007; Govorkova et al., 2011; Watanabe et al., 2013). As there are no antiviral drugs to 
treat viral conjunctivitis caused by respiratory viruses, it is necessary to assess the efficacy 
of currently available treatments to reduce viral replication in non-respiratory tissues such as 
the eye, in addition to examining drug efficacy when infection is initiated following virus 
exposure by non-respiratory routes.
A previous study from our laboratory demonstrated that oseltamivir inhibits H7 influenza 
virus replication in mice inoculated by the ocular route, with reductions in morbidity, 
mortality, and viral titers in both respiratory and ocular tissues in antiviral-treated mice 
(Belser et al., 2012b). However, there remains a need to better understand the capacity of 
currently available antiviral treatments to both inhibit virus spread from ocular sites to the 
respiratory tract and mitigate ocular disease caused by influenza virus infection. Here, we 
used a novel method of ocular-only aerosol (OA) inoculation of ferrets to investigate the 
ability of oseltamivir to prevent influenza virus infection, disease progression, and 
transmissibility following ocular exposure to influenza virus. We demonstrate that oral 
oseltamivir treatment effectively limits the establishment of a respiratory infection in ferrets 
exposed to aerosolized influenza virus by the ocular-only route, and reduces the 
transmission of viruses of multiple subtypes to naïve contacts when a respiratory infection 
results from ocular inoculation. Furthermore, we show that oseltamivir can limit influenza 
virus replication in human corneal epithelial cells.
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Results
Efficacy of oseltamivir administration following OA inoculation with H5N1 virus
Oseltamivir treatment has been shown to reduce morbidity, mortality, and systemic spread of 
HPAI H5N1 viruses in ferrets inoculated by the traditional intranasal route (Boltz et al., 
2008; Govorkova et al., 2007), but not following influenza virus infection by alternate 
exposure routes. As previous work found that the HPAI H5N1 virus A/Thailand/16/2004 
(Thai/16) was lethal to ferrets following ocular inoculation (Belser et al., 2014, 2012a), 
ferrets inoculated by the OA route with Thai/16 virus were orally administered 25 mg/kg of 
body weight/day of oseltamivir phosphate, or distilled water as a control, from 2 h p.i. 
through day 5 p.i. Both treated and control ferrets were monitored daily for clinical signs of 
illness, and nasal wash (NW), conjunctival wash (CW), and rectal swabs (RS) were collected 
on alternate days to assess virus replication.
Ferrets administered oseltamivir survived the H5N1 viral challenge, with transient weight 
loss and fever the only clinical signs and symptoms detected in this group (Table 1). While 
infectious virus was not detected in NW, CW, or RS samples during the acute phase of 
infection (Table 1, Fig. 1A), all treated ferrets seroconverted by day 21 p.i. (data not shown). 
In contrast, untreated ferrets inoculated by the OA route with the H5N1 virus succumbed to 
infection on days 5–7 p.i., presenting with weight loss, sustained fevers, nasal discharge, 
diarrhea, and neurological signs (Table 1). Virus was only detected sporadically and at low 
titer in NW (<200 PFU/mL), CW (<50 PFU/ mL), and RS (<600 PFU/mL) samples prior to 
euthanasia. However, postmortem necropsy revealed extensive systemic spread of virus in 
all untreated ferrets, including the respiratory tract, ocular tissue, and brain (Fig. 1B), with 
viral loads generally comparable to ferrets administered high doses of Thai/16 virus by the 
traditional intranasal route (Maines et al., 2005). In summary, we found that oseltamivir 
administration following OA inoculation with a HPAI H5N1 virus protected ferrets from a 
fatal, systemic infection.
Reduced virus transmissibility in ferrets receiving oseltamivir following OA inoculation
To examine a diverse range of viruses to which humans could potentially be exposed, we 
next challenged ferrets by the OA route with two influenza A viruses recently associated 
with human infection: the HPAI H7N3 virus A/Mexico/InDRE7218/2012 (Mex/7218) 
isolated from a poultry worker with conjunctivitis (Lopez-Martinez et al., 2013), and a 
representative 2009 H1N1 pandemic virus A/Mexico/4482/2009 (Mex/4482) isolated from a 
patient with severe respiratory disease (Maines et al., 2009). Both viruses have been shown 
previously to cause a moderate infection in ferrets following inoculation by the OA (Mex/
7218) or aerosol inhalation (AR) route (Mex/4482), and are capable of transmission in a 
ferret direct contact model (Belser et al., 2013a; Gustin et al., 2013). The efficacy of 
oseltamivir treatment to reduce virus virulence and transmissibility was examined for both 
viruses.
Similar to inoculation with Thai/16 virus, ferrets treated with oseltamivir and inoculated 
with the HPAI H7N3 virus Mex/7218 did not shed infectious virus in NW samples, whereas 
virus was detected in NW samples from both untreated ferrets (Fig. 2A). Moreover, 
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oseltamivir treatment of Mex/7218-inoculated ferrets was associated with reduced maximum 
weight loss (0–3%) compared with untreated ferrets (7.3–12.3%) (Table 1). Seroconversion 
to homologous virus was detected in two of three oseltamivir-treated ferrets and all untreated 
ferrets (data not shown). Transmission of virus to naïve cagemates was not detected in 
oseltamivir-treated ferrets (all contact ferrets remained seronegative at day 21 p.c.), while 
one of two untreated ferrets transmitted virus in the presence of direct contact 
(seroconversion was not detected in the ferret for which infectious virus was not recovered).
Oseltamivir treatment of ferrets inoculated by the OA route with Mex/4482 virus resulted in 
fewer ferrets shedding infectious virus in NW samples (1/3), reduced maximum weight loss 
(1.6–3.9%), and the absence of virus detected in naïve ferrets co-housed with inoculated 
animals (Table 1, Fig. 2B), compared with untreated ferrets, all of which shed virus in NW 
samples, exhibited greater maximum weight loss (5.8–13.7%), and transmitted virus to naïve 
ferrets (Table 1, Fig. 2B). Among naïve ferrets co-housed with oseltamivir-treated ferrets, 
only one ferret exhibited seroconversion to Mex/4482 virus (the cagemate to the inoculated 
ferret with positive NW detection), with no seroconversion detected in other contact ferrets 
(Fig. 2B and data not shown). These results show that oseltamivir treatment can lead to 
diminished pathogenicity and transmissibility of numerous virus subtypes following OA 
exposure.
Efficacy of oseltamivir following joint ocular-respiratory aerosol exposure of ferrets
In the absence of either respiratory or ocular protection, a joint ocular-respiratory exposure 
represents a probable exposure event for individuals in community settings. To more closely 
mimic a ‘natural’ human exposure, we exposed ferrets to aerosolized LPAI H7N9 A/Anhui/
1/2013 (Anhui/1) influenza virus by the OA route with or without concurrent low-level (1.2–
11 PFU) AR exposure (Table 1, Fig. 3A and B). Control ferrets received an ocular-only 
exposure to virus (Fig. 3C). The virus Anhui/1, isolated from a fatal case at the beginning of 
the H7N9 outbreak in 2013, represents a current public health threat for which both 
respiratory and ocular exposure of humans is possible (Gao et al., 2013).
Unlike H5N1, H7N3, or H1N1 OA challenges, virus was detected in NW specimens of all 
oseltamivir-treated ferrets infected with H7N9 virus by either OA only or joint OA-AR 
exposure (Fig. 3A and B). Clinical signs and symptoms were generally comparable between 
oseltamivir-treated and untreated ferrets, and all inoculated ferrets mounted a respiratory 
infection (Table 1). Untreated ferrets inoculated with Anhui/1 virus efficiently transmitted 
virus to 100% of cagemates when placed in direct contact, with virus detected in NW 
specimens from all animals by day 3 p.c. (Fig. 3C). In contrast, transmission among ferrets 
exposed to Anhui/1 virus by the OA route or OA-AR route and treated with oseltamivir was 
less efficient, with transmission was detected in 2/2 and 2/4 ferret pairs, respectively (Fig. 
3A and B). Compared with control ferrets, transmission events were delayed (with onset of 
virus detection in contact ferrets day 9 p.c.) or resulted in reduced replication in contacts 
(with peak titers in NW specimens from contact ferrets <200 PFU/mL). In summary, we 
found that oseltamivir treatment limited the establishment of a transmissible respiratory 
infection in ferrets exposed to aerosolized LPAI H7N9 influenza virus by both ocular and 
joint ocular-respiratory routes.
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Inhibitory activity of oseltamivir carboxylate in human respiratory and ocular cells
While our results in the ferret model agree with previous work demonstrating reduced viral 
loads in ocular tissue of oseltamivir-treated mice (Belser et al., 2012b), the efficacy of 
oseltamivir specifically within human ocular tissue has not been studied. We examined the 
susceptibility of influenza viruses to oseltamivir carboxylate in primary human corneal 
epithelial cells (HCEpiC) and compared with the human bronchial epithelial cell line Calu-3 
and MDCK cells. All cell types have been shown previously to support productive 
replication of human and avian influenza viruses (Belser et al., 2011b). Cells were infected 
with influenza viruses at a MOI of 0.001, and cultured in the presence of serially diluted 
non-cytotoxic quantities of oseltamivir carboxylate to determine reductions of virus yield.
All influenza viruses tested demonstrated sensitivity to oseltamivir carboxylate in all cell 
types examined. Treatment with 100 mm of oseltamivir carboxylate limited viral titers of 
H7N3, H7N9, and H1N1 viruses to <102 PFU/ml at 24 h and <103.3 PFU/ml at 48 h p.i (Fig. 
4). At this concentration of drug, viral titers of the HPAI H5N1 virus Thai/16 were reduced 
by 4.3–5.8 logs compared with control-treated cultures at 24 h p.i. While the reductions in 
viral yield observed following oseltamivir carboxylate treatment varied between cell types in 
a strain-specific manner, with greater fold reductions in titer observed for viruses that 
replicated robustly in the absence of oseltamivir, dose-dependent inhibition was observed for 
all viruses tested regardless of replication efficiency. Comparable results were observed at a 
MOI of 0.01 (data not shown). These results indicate that, similar to human respiratory tract 
cells, treatment of human ocular cells with oseltamivir carboxylate effectively inhibits viral 
yields early after infection.
Discussion
Neuraminidase inhibitors are frequently employed to limit influenza virus infection and 
spread following respiratory exposure. Understanding how inoculation route and inoculation 
dose modulate the resulting severity of disease in humans has obvious implications for 
clinical treatment and mitigation of transmission to susceptible contacts. As the eye 
represents a secondary mucosal surface bearing permissive viral receptors, located proximal 
to the nasal passages and as such likely co-exposed during respiratory inhalation of virus, we 
chose ocular inoculation as a model non-respiratory inoculation route to study this property 
(Belser et al., 2013b). The utility of the ferret model to study viral conjunctivitis has been 
previously reported (Kirkeby et al., 2013); while influenza virus-infected ferrets do not 
typically display macroscopic ocular disease, the close physiologic relatedness between 
ferrets and humans warrants the use of this species to study ocular exposure and the efficacy 
of antiviral treatment following infection (Belser et al., 2011a).
Ocular inoculation of influenza viruses in mammalian models typically leads to delays 
and/or reductions in symptom onset and virus detection compared with traditional intranasal 
inoculation (Aamir et al., 2009; Belser et al., 2014, 2012a, 2009; Sun et al., 2009). Despite 
differential kinetics between inoculation routes, oseltamivir treatment administered orally 
for the standard 5 days p.i. was sufficient to abrogate detectable virus replication in the 
upper respiratory tract of treated ferrets with two HPAI viruses (Figs. 1 and 2), and further 
limit the establishment of a respiratory infection in ferrets exposed to aerosolized LPAI or 
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2009 pandemic influenza virus by the OA route. Each virus is processed differently during 
aerosolization; while challenge doses varied between viruses used in this study, inoculating 
doses of all ferrets for each virus were generally equivalent (within one log) (Table 1). Of 
note, the 2009 H1N1 virus Mex/4482 is highly infectious, with low inoculating doses (<1 
PFU of total OA exposure) sufficient to mount a productive respiratory infection in untreated 
ferrets (Table 1). This low inoculating dose was necessary to demonstrate oseltamivir 
efficacy as inoculation with high doses of this virus has been shown previously to limit 
abrogation of virus in NW specimens from drug-treated ferrets (Govorkova et al., 2011; 
Marriott et al., 2014). In accord, while viral titers in Anhui/1 OA and OA-AR virus-
challenged ferrets were reduced and delayed compared with control ferrets, the sustained 
detection of virus in NW specimens from these groups may in part be due to the relatively 
higher inoculating dose use in this challenge (>100 PFU) (Table 1).
Human cases of influenza resulting from a known ocular exposure are typically self-
limiting, though documented instances of probable person-to-person transmission have been 
reported (Koopmans et al., 2004). Furthermore, viruses not typically associated with an 
ocular tropism, such as the 2009 H1N1 pandemic virus, have nonetheless been found 
capable to cause ocular symptoms in infected individuals (Mansour et al., 2012). Thus, our 
finding that oseltamivir treatment following ocular exposure reduces virus transmission to 
naïve contacts when a respiratory infection is established supports the use of antiviral 
treatments in outbreak settings where ocular symptoms such as conjunctivitis are the 
primary manifestation of disease. Comparable results between ferrets receiving an ocular-
only aerosol dose of Anhui/1 virus and those receiving a concurrent ocular and low-level 
(~10 PFU) respiratory exposure demonstrates the utility of antiviral treatment following a 
more rigorous virus exposure (Fig. 3). This is of particular note as select avian influenza 
viruses have caused concurrent ocular and respiratory disease (Avian influenza, 2007; Tam, 
2002; Tweed et al., 2004; Writing Committee of the Second World Health Organization 
Consultation on Clinical Aspects of Human Infection et al., 2008), and in the absence of 
personal protective equipment, simultaneous exposure of both respiratory and ocular tissues 
is likely. Our results further suggest that oseltamivir prophylaxis of naïve cagemates would 
offer comparable levels of protection as has been observed following traditional intranasal 
inoculation of ferrets (Oh et al., 2014). Previous work in the ferret model has demonstrated 
that oral administration of oseltamivir does not typically generate drug-resistant variants 
during the acute phase of infection (Govorkova et al., 2007, 2011); nonetheless, future 
studies examining ocular exposure to oseltamivir-resistant influenza viruses and the role of 
oseltamivir drug-resistance in the context of ocular infection is warranted.
The human eye and surrounding conjunctiva possess numerous discrete cell types which are 
permissive to influenza virus infection (Belser et al., 2011b; Chan et al., 2010; Michaelis et 
al., 2009). While the mechanisms underlying viral conjunctivitis associated with H7 subtype 
viruses are poorly understood, high viral loads leading to increased inflammation in ocular 
tissue may represent a contributing factor (Chan et al., 2010). The majority of antiviral drugs 
available to treat viral conjunctivitis are targeted towards herpesvirus and adenovirus 
infection; ocular disease caused by RNA viruses such as influenza or RSV currently lack 
commercially available antiviral drug treatments (Skevaki et al., 2011). The high 
bioavailability of oseltamivir following oral administration (Davies, 2010; Wattanagoon et 
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al., 2009) likely contributes to the reduced viral titers observed in ocular tissue following 
ocular inoculation of either mice or ferrets with influenza viruses (Belser et al., 2012b). Our 
finding that oseltamivir reduces influenza virus titers in human ocular cells in a dose-
dependent manner is in agreement with these studies (Fig. 4).
Influenza virus pathogenicity and transmissibility in mammals represent multifactorial traits, 
with numerous host and viral factors contributing to disease severity. Recent advances in 
mammalian modeling of influenza viruses have illustrated that exposure route and dose can 
similarly influence the presentation of clinical signs and symptoms of disease (Gustin et al., 
2012). Accordingly, prevention and control measures must be evaluated in settings which 
reflect the heterogeneity intrinsic in human exposure. While this study examined ocular-only 
virus exposure, using fixed concentrations of virus for each ferret challenge and a fixed 
exposure time, further modulation and characterization of inoculation parameters in 
mammalian models will allow for both a broader understanding of the inherent variability in 
influenza virus virulence as well as provide greater guidance in the development, 
assessment, and use of anti-influenza stratagems.
Methods
Viruses
Influenza A viruses used in this study are shown in Table 1. Virus stocks were propagated in 
the allantoic cavity of 10-day-old embryonated hens' eggs (Maines et al., 2005), and virus 
stock titers were determined by standard plaque assay using Madin-Darby canine kidney 
cells (MDCK) (ATCC, Manassas, VA) (Zeng et al., 2007). All experiments were conducted 
under biosafety level 3 containment, including enhancements as required by the U.S. 
Department of Agriculture and the National Select Agent Program (Chosewood and Wilson, 
2009).
Inoculation and assessment of drug efficacy in ferrets
Male Fitch ferrets (Triple F Farms) were 6-to-8 months old and serologically negative by 
hemagglutination inhibition assay to currently circulating influenza viruses (H1N1 [2009 
pandemic], H3N2 [A/Perth/16/2009], and B [Yamagata and Victoria lineages]. Ferrets were 
housed in a Duo-Flo Bioclean mobile environmental enclosure (Lab Products, Seaford, DE) 
for the duration of each experiment. Ocular-only aerosol (OA) inoculation of ferrets were 
performed by passing aerosolized virus through aerosol-delivery goggles fitted on sedated 
ferrets (Belser et al., 2014). The ocular dose presented to each ferret was calculated by 
multiplying the concentration of virus in the aerosol by the exposure time; all ferrets 
inoculated by the OA-only route received <1 PFU of respiratory exposure. Ferrets which 
received ≥1 PFU of respiratory exposure (measured by sampling the air inside the secondary 
animal holding chamber) were either excluded from the study or studied for joint ocular-
respiratory exposure (Table 1). Ferrets received control (distilled, sterile water) or 25 mg/kg 
of body weight/day oseltamivir phosphate (Sequoia Research Products, United Kingdom) 
suspended in 15% fructose orally twice daily (12.5 mg/kg per dose) from 2 h post-
inoculation (p.i.) through day 5 p.i.
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Ferrets were monitored daily for morbidity and clinical signs of infection for 14 days p.i. 
(Maines et al., 2005). Any ferret which lost >25% of its preinoculation body weight or 
exhibited neurological dysfunction was euthanized and submitted to postmortem 
examination. Virus shedding was measured in nasal wash, conjunctival wash, and rectal 
swab samples (Belser et al., 2012a). Naïve ferrets were placed in the same cage as 
inoculated ferrets to measure virus transmission in the presence of direct contact, with serum 
collected 17-to-23 days p.i./post-contact (p.c.) to measure seroconversion by hemagglutinin 
inhibition (Maines et al., 2006). Animal research was conducted in an Association for 
Assessment and Accreditation of Laboratory Animal Care International-accredited facility, 
under the guidance of the CDC's Institutional Animal Care and Use Committee.
Cell culture and viral infection
The bronchial epithelial cell line Calu-3 (ATCC) was cultured on 6-well membrane inserts 
(Zeng et al., 2007). Primary human corneal epithelial cells (HCEpiC, ATCC) were grown to 
confluence in 12-well plates in serum-free medium. MDCK cells were grown to confluence 
in 6-well plates. Virus was added apically at a multiplicity of infection (MOI) of 0.01 or 
0.001 for one hour before washing. To assess reduction of influenza virus yields by 
oseltamivir carboxylate in each cell type, cell type-specific serum-free media containing 
indicated concentrations (0–100 µM) of oseltamivir carboxylate (Sequoia) was added to the 
cultures (Ilyushina et al., 2006), with the addition of 300 µg/liter N-p-tosyl-L-phenylalanine 
chloromethyl ketone (TPCK-trypsin) in HCEpiC and MDCK cultures. Aliquots of apical 
culture supernatants were harvested at indicated times p.i. and titered for the presence of 
infectious virus by standard plaque assay.
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Fig. 1. 
Oseltamivir efficacy following OA inoculation of ferrets with HPAI H5N1 virus. Ferrets 
were inoculated by the OA route with Thai/16 virus at the doses reported in Table 1 and 
administered oseltamivir phosphate or distilled water as a control (n = 3 per group). (A), 
viral titers in nasal wash specimens were determined on the indicated days p.i. (B), tissues 
collected from control-treated ferrets euthanized due to neurological symptoms days 5–7 p.i. 
were titered for presence of infectious virus by standard plaque assay. NT, nasal turbinates; 
Tr, trachea; Lg, lung; BnOB, olfactory bulb; BnAnt, anterior brain; BnPos, posterior brain; 
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Conj, conjunctiva; Lv, liver; Kd, kidney; Sp, spleen; Int, pooled intestine; Bd, blood. Bars 
represent individual ferrets. Limit of detection was 10 PFU/ml or g.
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Fig. 2. 
Reduced influenza virus transmissibility in ferrets receiving oseltamivir following OA 
inoculation. Ferrets were inoculated by the OA route with Mex/7218 virus (A) or Mex/4482 
virus (B) at the doses reported in Table 1 and administered oseltamivir phosphate (left 
column) or distilled water as a control (right column). A naïve ferret was placed in the same 
cage as each inoculated ferret at 24 h p.i. in order to assess virus transmission in the 
presence of direct contact. Nasal washes were collected from inoculated and contact ferrets 
on alternate days p.i. (solid bars) or p.c. (hatched bars). The limit of virus detection was 10 
PFU/mL.
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Fig. 3. 
Reduced H7N9 virus transmissibility in oseltamivir-treated ferrets receiving ocular-only or 
joint ocular-respiratory exposure. Oseltamivir-treated ferrets were inoculated by the OA 
route without (A) or with (B) respiratory (AR) exposure to Anhui/1 virus at the doses 
reported in Table 1, or inoculated by the OA route without respiratory exposure and 
administered distilled water as a control (C). A naïve ferret was placed in the same cage as 
each inoculated ferret at 24 h p.i. in order to assess virus transmission in the presence of 
direct contact. Nasal washes were collected from inoculated and contact ferrets on alternate 
days p.i. (solid bars) or p.c. (hatched bars). The limit of virus detection was 10 PFU/mL.
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Fig. 4. 
Reduction of influenza virus yield by oseltamivir carboxylate in multiple cell types. MDCK 
(A), Calu-3 (B), or HCEpiC (C) cells were infected with H5N1, H7N9, H7N3, or H1N1 
viruses at a MOI of 0.001 and cultured p.i. with medium containing the indicated quantity of 
oseltamivir carboxylate. 24 h (left column) or 48 h (right column) p.i., culture supernatant 
was sampled and titered for the presence of infectious virus by plaque assay. Values 
represent the mean+standard deviation for triplicate wells; limit of detection was 10 
PFU/mL.
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